New Clinical Trial Investigates Novel Lung Cancer 'Nanomedicine' | Lung Cancer Dispatch |

A new phase II clinical trial is investigating the new cancer drug BIND-014 as a second-line treatment for non-small cell lung cancer (NSCLC). BIND-014 is part of a group of 'nanoengineered' drugs called Accurins, which consist of: 1) targeting particles that direct them preferentially to the disease site–in the case of BIND-014, these particles bind to PSMA, a protein expressed on cancer cells; 2) a 'stealth layer' protecting them from the body's immune system; 3) a controlled-release structure ensuring that the 'payload' is released at the optimal rate; and 4) the drug's actual payload–in the case of BIND-014, the chemotherapy agent docetaxel (Taxotere). Accurins are designed to maximize the drug concentration delivered to the tumor, while minimizing toxicity to healthy tissues.